MX2021006802A - Conjugados. - Google Patents

Conjugados.

Info

Publication number
MX2021006802A
MX2021006802A MX2021006802A MX2021006802A MX2021006802A MX 2021006802 A MX2021006802 A MX 2021006802A MX 2021006802 A MX2021006802 A MX 2021006802A MX 2021006802 A MX2021006802 A MX 2021006802A MX 2021006802 A MX2021006802 A MX 2021006802A
Authority
MX
Mexico
Prior art keywords
alkenylene
formula
active agent
conjugate
alkylene
Prior art date
Application number
MX2021006802A
Other languages
English (en)
Spanish (es)
Inventor
Alan Lawson Sewell
Ezequiel Silva Nigenda
Sean Niall O''byrne
Ricardo Lopez-Gonzalez
Rodolfo Marquez
Original Assignee
Transfection Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transfection Holdings Ltd filed Critical Transfection Holdings Ltd
Publication of MX2021006802A publication Critical patent/MX2021006802A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0045—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent agent being a peptide or protein used for imaging or diagnosis in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0052—Small organic molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
MX2021006802A 2018-12-18 2019-12-18 Conjugados. MX2021006802A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1820626.8A GB201820626D0 (en) 2018-12-18 2018-12-18 Conjugates
PCT/EP2019/086120 WO2020127602A1 (en) 2018-12-18 2019-12-18 Conjugates

Publications (1)

Publication Number Publication Date
MX2021006802A true MX2021006802A (es) 2021-08-16

Family

ID=65147114

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021006802A MX2021006802A (es) 2018-12-18 2019-12-18 Conjugados.

Country Status (11)

Country Link
US (1) US20220054658A1 (cg-RX-API-DMAC7.html)
EP (1) EP3897737A1 (cg-RX-API-DMAC7.html)
JP (2) JP2022514335A (cg-RX-API-DMAC7.html)
KR (1) KR20210106496A (cg-RX-API-DMAC7.html)
CN (1) CN113474007A (cg-RX-API-DMAC7.html)
AU (1) AU2019400788A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021011860A2 (cg-RX-API-DMAC7.html)
CA (1) CA3123960A1 (cg-RX-API-DMAC7.html)
GB (1) GB201820626D0 (cg-RX-API-DMAC7.html)
MX (1) MX2021006802A (cg-RX-API-DMAC7.html)
WO (1) WO2020127602A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114685430B (zh) * 2022-03-18 2023-07-21 浙江大学 芬苯达唑类似物及制备方法和应用
WO2024049306A1 (en) * 2022-08-31 2024-03-07 Lopez Gonzalez Ricardo Chemical conjugates, compositions, and methods of preparation and use thereof
CN120987848B (zh) * 2025-07-10 2026-07-21 广州大学 一种含胍基结构单元的ε-己内酰胺化合物及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0068485B1 (en) 1981-07-01 1987-11-11 Sanraku Incorporated Novel antibiotics and process for production thereof
EP2370411A4 (en) * 2008-12-05 2012-10-24 Univ Oregon Health & Science COMPOUNDS WITH ANTIPARASITIC OR ANTI-INFECTIOUS EFFECT
JP5852658B2 (ja) * 2010-09-24 2016-02-03 ザ リージェンツ オブ ザ ユニバーシティー オブ ミシガン デユビキチナーゼ阻害剤およびその使用方法
US20130345270A1 (en) * 2010-11-12 2013-12-26 Waake Forest University Health Sciences Methods of treating cancer and other disorders
EP2665738B1 (en) 2011-01-18 2018-09-26 The Royal Institution for the Advancement of Learning/McGill University Aminoglycosides for use in the treatment of bacterial infection
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
ES2907461T3 (es) * 2015-01-20 2022-04-25 Boehringer Ingelheim Animal Health Usa Inc Compuestos antihelmínticos, composiciones y procedimientos de uso de los mismos
WO2019060634A1 (en) 2017-09-20 2019-03-28 Thiogenesis Therapeutics, Inc. METHODS OF TREATING CYSTEAMINE SENSITIVE DISORDERS

Also Published As

Publication number Publication date
GB201820626D0 (en) 2019-01-30
KR20210106496A (ko) 2021-08-30
JP2025072404A (ja) 2025-05-09
JP2022514335A (ja) 2022-02-10
US20220054658A1 (en) 2022-02-24
WO2020127602A1 (en) 2020-06-25
EP3897737A1 (en) 2021-10-27
CA3123960A1 (en) 2020-06-25
AU2019400788A1 (en) 2021-08-12
CN113474007A (zh) 2021-10-01
BR112021011860A2 (pt) 2021-09-08

Similar Documents

Publication Publication Date Title
CO2022002685A2 (es) Nanopartículas lipídicas mejoradas para el suministro de ácidos nucleicos
MX2021011296A (es) Composiciones para el cuidado bucal para el suministro de agente activo.
CL2020000220A1 (es) Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial.
EA202191559A1 (ru) Модифицированные аминовые липиды
MX2020005621A (es) Derivados de acidos grasos para tratar la esteatohepatitis no alcoholica.
MX2021003455A (es) Lípidos con amina ionizables.
PE20200701A1 (es) Agonistas del receptor tipo toll 7 (tlr7) que tienen una porcion heterobiarilo, conjugados de estos y metodos y usos de estos
CR20210201A (es) Nuevos compuestos antihelmínticos
MX2019005379A (es) Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo.
PE20220017A1 (es) Inhibidores del kcnt1 y metodos de uso
CL2020002252A1 (es) Formulación oftálmica.
CL2016001041A1 (es) Implante intraocular biodegradable que contiene una matriz de polimero biodegradable, polietilenglicol 3350 y una prostamida; uso del mismo en la reducción de la presion ocular en el ojo de un mamifero; aparato para administrar el implante intraocular biodegradable; y método para confeccionar un implante intraocular biodegradable.
MX2021011297A (es) Composiciones para el cuidado bucal para el suministro de agente activo.
MX393613B (es) Composiciones de gel para administracion transdermica para maximizar las concentraciones de farmaco en el estrato corneo y suero, y metodos de uso de las mismas.
MX385752B (es) Composiciones de disulfuro de selenio para usarse en el tratamiento de la disfunción de las glándulas de meibomio.
CL2012000446A1 (es) Uso de una formulación vesicular tópica que comprende uno o más fosfolípidos y uno o más tensoactivos en una razón molar de 1:1 a 25:1 de fosfolípidos a tensoactivos, para el tratamiento de trastornos dermatosos inflamatorios.
NI201100201A (es) Metodo y composición para el control de parásitos
MX2023006504A (es) Compuesto de hidroxamato, metodo de preparacion del mismo y aplicacion del mismo.
PE20151327A1 (es) Heterociclos n-acetilados y de nitrogeno saturados que potencian la actividad de un antibiotico activo contra micobacterias
CO6480985A2 (es) Formulaciones para el tratamiento del dolor tisular profundo
MX2021005801A (es) Metodos para administrar corticosteroides.
CO2021004681A2 (es) Uso de reboxetina para el tratamiento de narcolepsia
MX2016014411A (es) Formulacion liquida que comprende un compuesto neutralizante de gm-csf.
MX2022006882A (es) Formulaciones de anticuerpos anti-cd38 para administracion subcutanea.
MX385380B (es) Formulacion topica para promover la curacion de heridas.